Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

Abstract: Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective: The authors assessed the efficacy and safety of r...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, Tianshuang Wu, Ranjeeta Sinvhal, Vassilis Stakias, Alexandra P. Song, Jasmina Kalabic, Naomi Martin, Luiza Keiko Matsuka Oyafuso
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Sociedade Brasileira de Dermatologia 2025-04-01
Edice:	Anais Brasileiros de Dermatologia
Témata:	Methotrexate Psoriasis Risankizumab
On-line přístup:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962025000200308&lng=en&tlng=en
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!